Sugi Predict

Sugi Predict / Compounds / SCHEMBL782333

SCHEMBL782333

SCHEMBL782333

O=C(O)[C@H]1O[C@@H](O)[C@H](OS(=O)(=O)O)[C@@H](O)[C@@H]1O

nearest known ligand 0.41

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
▸ CXCL10 P02778 1/20 0.40
▸ CXCL8 P10145 1/20 0.40
▸ CCL2 P13500 1/20 0.40
▸ CCL5 P13501 1/20 0.40
▸ CXCL12 P48061 1/20 0.40
▸ IDUA P35475 1/20 0.35
▸ SUCNR1 Q9BXA5 1/20 0.33
▸ BDNF P23560 2/20 0.32
▸ PTN P21246 1/20 0.32
▸ MDK P21741 1/20 0.32
▸ F10 P00742 2/20 0.32
▸ FGF2 P09038 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21840769 1.00 CXCL10 (0.40) CXCL10CXCL8CCL2CCL5CXCL12
SCHEMBL28725193 1.00 CXCL10 (0.40) CXCL10CXCL8CCL2CCL5CXCL12
SCHEMBL28460941 1.00 CXCL10 (0.40) CXCL10CXCL8CCL2CCL5CXCL12
SCHEMBL29535400 1.00 CXCL10 (0.40) CXCL10CXCL8CCL2CCL5CXCL12
SCHEMBL7580018 1.00 CXCL10 (0.40) CXCL10CXCL8CCL2CCL5CXCL12
SCHEMBL29420392 1.00 CXCL10 (0.40) CXCL10CXCL8CCL2CCL5CXCL12
SCHEMBL17847369 1.00 CXCL10 (0.40) CXCL10CXCL8CCL2CCL5CXCL12
SCHEMBL22712706 1.00 CXCL10 (0.40) CXCL10CXCL8CCL2CCL5CXCL12
SCHEMBL30448178 0.89 CXCL10 (0.40) CXCL10CXCL8CCL2CCL5CXCL12
SCHEMBL30403519 0.89 CXCL10 (0.49) CXCL10CXCL8CCL2CCL5CXCL12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 110 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3018177-B1 STABILIZATION OF CARBON NANOTUBE COATINGS BATTELLE MEMORIAL INSTITUTE (US) 2023-08-02 — — EP claimed
US-10982101-B2 Stabilization of carbon nanotube coatings BATTELLE MEMORIAL INSTITUTE (US) 2021-04-20 — — US claimed
US-20200283645-A1 Stabilization of Carbon Nanotube Coatings BATTELLE MEMORIAL INSTITUTE (US) 2020-09-10 — — US claimed
US-20160137854-A1 STABILIZATION OF CARBON NANOTUBE COATINGS TO MOISTURE BATTELLE MEMORIAL INSTITUTE 2016-05-19 — — US claimed
EP-3018177-A2 STABILIZATION OF CARBON NANOTUBE COATINGS BATTELLE MEMORIAL INSTITUTE (US) 2016-05-11 — — EP claimed
EP-4370324-A1 THIN, FLEXIBLE, TUNABLE INFRARED EMISSIVITY BASED ON CARBON NANOTUBES Battelle Memorial Institute (US) 2024-05-22 — — EP disclosed
US-20230391049-A1 Flexible Foam Resistive Heaters and Methods of Making Flexible Resistive Heaters BATTELLE MEMORIAL INSTITUTE 2023-12-07 — — US disclosed
US-20230355176-A1 ELECTRICALLY CONDUCTIVE MATERIALS BATTELLE MEMORIAL INSTITUTE 2023-11-09 — — US disclosed
US-20230310700-A1 DERMAL FILLER COMPOSITIONS INCLUDING ANTIOXIDANTS ALLERGAN IND SAS (FR) 2023-10-05 — — US disclosed
US-11760056-B2 Flexible foam resistive heaters and methods of making flexible resistive heaters BATTELLE MEMORIAL INSTITUTE (US) 2023-09-19 — — US disclosed
US-20230269833-A1 Transparent CNT Heaters for Laminated Glass BATTELLE MEMORIAL INSTITUTE 2023-08-24 — — US disclosed
EP-3018177-B1 STABILIZATION OF CARBON NANOTUBE COATINGS BATTELLE MEMORIAL INSTITUTE (US) 2023-08-02 — — EP disclosed
US-20120071437-A1 TUNABLE CROSSLINKED POLYSACCHARIDE COMPOSITIONS ALLERGAN, INC. (US) 2012-03-22 — — US disclosed
US-20110224164-A1 FLUID COMPOSITIONS FOR IMPROVING SKIN CONDITIONS ALLERGAN INDUSTRIE, SAS (FR) 2011-09-15 — — US disclosed
US-20110189292-A1 DERMAL FILLERS COMPRISING SILK FIBROIN HYDROGELS AND USES THEREOF ALLERGAN, INC. (US) 2011-08-04 — — US disclosed
US-20110171311-A1 STABLE HYDROGEL COMPOSITIONS INCLUDING ADDITIVES ALLERGAN INDUSTRIE, SAS (FR) 2011-07-14 — — US disclosed
US-20110171310-A1 HYDROGEL COMPOSITIONS COMPRISING VASOCONSTRICTING AND ANTI-HEMORRHAGIC AGENTS FOR DERMATOLOGICAL USE ALLERGAN INDUSTRIE, SAS (FR) 2011-07-14 — — US disclosed
US-20110077737-A1 Tunably Crosslinked Polysaccharide Compositions ALLERGAN, INC. (US) 2011-03-31 — — US disclosed
US-6846917-B2 Solid- and solution-phase synthesis of heparin and other glycosaminoglycans MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2005-01-25 — — US disclosed
US-20030013862-A1 Solid- and solution-phase synthesis of heparin and other glycosaminoglycans NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2003-01-16 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030013862-A1 Solid- and solution-phase synthesis of heparin and other glycosaminoglycans HPSE, TLR3, HDGF CXCL10 775/4885CXCL8 1500/4885CCL2 708/4885
US-20120071437-A1 TUNABLE CROSSLINKED POLYSACCHARIDE COMPOSITIONS CD44, COL2A1, FN1 CXCL10 254/4885CXCL8 911/4885CCL2 579/4885
US-20110077737-A1 Tunably Crosslinked Polysaccharide Compositions ALG1, CD44, COL2A1 CXCL10 209/4885CXCL8 692/4885CCL2 423/4885
US-20110224164-A1 FLUID COMPOSITIONS FOR IMPROVING SKIN CONDITIONS CUTA, KRT18, MATR3 CXCL10 374/4885CXCL8 100/4885CCL2 723/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.